Analysis of continuous patient data from the Czech National Register of patients with type 1 and type 2 diabetes using insulin pump therapy
| Autor: | Haladová I, Jankovec Z, Markus Hahn, Michal Zourek, Michal Krcma, S. Grunder, Cechurová D, Zdenek Rusavy, Silvie Lacigová |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Insulin pump medicine.medical_specialty Complete data Endocrinology Diabetes and Metabolism Type 2 diabetes Body Mass Index Diabetes Complications Insulin Infusion Systems Endocrinology Internal medicine Diabetes mellitus Internal Medicine medicine Humans Registries Diabetes types Adverse effect Czech Republic Glycated Hemoglobin business.industry General Medicine Patient data Middle Aged medicine.disease Surgery Safety profile Diabetes Mellitus Type 1 Diabetes Mellitus Type 2 Female Safety business |
| Zdroj: | Diabetes Research and Clinical Practice. 87:219-223 |
| ISSN: | 0168-8227 |
| DOI: | 10.1016/j.diabres.2009.09.028 |
| Popis: | Aim Patient data from the Czech National Register of patients treated with Continuous Subcutaneous Insulin Infusion (CSII) were evaluated to compare treatment indication, efficacy and safety with specific regard to the type of diabetes (T1 vs. T2). Methods Evaluation was done on complete data sets of at least 3 years from patients with either T1 diabetes ( n = 730, 93.1%) or T2 diabetes ( n = 54, 6.9%) between 1995 and 2006. Results HbA 1c decreased from 9.65 (±0.07) and 9.66 (±0.05) for T1 and T2 respectively to 8.24 (±0.07) for T1 and 8.52 (±0.27) for T2 after 1 year of treatment, 8.34 (±0.07) and 8.54 (±0.26) after 2 years and 8.44 (±0.07) and 8.71 (±0.25) after 3 years (adjusted mean values, ±SEM). This reduction is significant for both diabetes types. Results gathered from the safety analysis revealed almost comparable results for both patient groups (rates of adverse events of 42.5 and 34.8 for T1 and T2, per 100 patients and year). Conclusion Both patient groups achieved substantial reduction of HbA 1c . Safety evaluation showed that fewer patients with T2 diabetes were affected by adverse events. According to that CSII treatment for patients with T2 diabetes is similarly effective with a slightly better safety profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect